Sotera Health (SHC) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.29
- Estimate
- $0.27
- Surprise
- +8.0%
- Revenue (period 2026-09-30)
- $324.9M
- Score today
- 6.0/10
Revenue source: xbrl.
How the report landed
Sotera Health (SHC) beat the $0.27 estimate with adjusted EPS of $0.29 — a clear 8.0% upside surprise.
Coverage in the report window
- Sotera Health Affirms FY2026 Adj EPS Guidance of $0.95-$1.01 vs $0.98 Est; Lowers FY2026 Sales Guidance from $1.236B-$1. — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates SHC Sell at 6.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +8.0% surprise compares with a +6.8% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: EO single supplier
- Leverage penalty (D/E 3.4): -1.5
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.03
- Price target
- $19.67
- Stop
- $15.42
- Upside to target
- +22.7%
- Reward-to-risk
- 3.0:1
The stock trades at 26.7× trailing but 14.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.3× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
SHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $4.57B
- P/E (fwd)
- 14.8
- P/E (ttm)
- 26.7
- 52-week range
- $13.09–$19.85
- Off 52-week high
- 19.2%
- RSI (14)
- 33
- Volume vs avg
- 2.31×
- Score today
- 6.0/10